Dolby Laboratories (NYSE: DLB) rose 11% after it reported fourth quarter results that beat analysts' estimates on the bottom line. On a non-GAAP basis, f ...

A phase 2b trial of Viking Therapeutics' (NASDAQ:VKTX) VK2809 found that those on the medicine saw statistically significant ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective ...

Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients ...

On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...

There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...